Proactive Investors - Run By Investors For Investors

New long-term NHS plan bodes well for ValiRx

The ten-year plan, set out on Monday, includes a greater focus on earlier detection of cancers and personalised medicines, both of which ValiRx specialises in
hospital ward
ValiRx is focused on developing new treatments for cancer

ValiRx PLC (LON:VAL) has given its support to the UK government’s new long-term plan, which was unveiled on Monday.

In the ten-year plan, NHS bosses said they wanted to find ways to detect cancers earlier. Currently, only half of the people diagnosed with the disease are identified early on – at stage one or two.

READ: ValiRx hopes to expedite partner discussions with peer review of lung cancer treatment

“ValiRx is an innovative biotechnology company developing novel and improved therapeutics, both in the UK and globally,” said chief executive Satu Vainikka.

“The government's recently announced ten-year plan of investing in the prevention and early diagnosis of diseases, such as certain neurological, mental and oncological diseases, is a policy that we have been following and striving to address for some time.”

ValiRx’s lead anti-cancer compound, VAL401, performed well in a Phase II study last year, with results showing that palliative stage lung cancer patients could expect to see improvements in quality of life as well as improved survival prospects.

Its other clinical stage compound, VAL201 has “performed extremely well” in its Phase I/II prostate cancer trial so far.

Personalised medicines

The 136-page report also set out plans to pour more money into personalised medicine, especially in the treatment of cancers.

Traditional treatments such as chemotherapy are what are called non-specific agents, but scientists are increasingly finding ways to develop targeted drugs that ‘suit’ a particular subset of patients, making them more effective.

ValiRx shares edged 0.5% higher in late-morning trading to 0.83p.

View full VAL profile View Profile

ValiRx Plc Timeline

Big Picture
May 02 2019

Related Articles

Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
A doctor's stethoscope and a marijuana plant
February 22 2019
With top-line data from the CONNECT-FX trial on the way, investors are eying the opportunity defined by marijuana-adjacent companies like Zynerba Pharmaceuticals

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use